©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Site of Covalent Labeling by a Photoreactive Batrachotoxin Derivative near Transmembrane Segment IS6 of the Sodium Channel Subunit (*)

(Received for publication, December 26, 1995)

Vera L. Trainer George B. Brown (1) William A. Catterall

From the Department of Pharmacology, University of Washington, Seattle, Washington 98195 Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama 35924

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The binding site for batrachotoxin, a lipid-soluble neurotoxin acting at Na channel receptor site 2, was localized using a photoreactive, radiolabeled batrachotoxin derivative to covalently label purified and reconstituted rat brain Na channels. In the presence of the brevetoxin 1 from Ptychodiscus brevis and the pyrethroid RU51049, positive allosteric enhancers of batrachotoxin binding, a protein with an apparent molecular mass of 240 kDa corresponding to the Na channel alpha subunit was specifically covalently labeled. The region of the alpha subunit specifically photolabeled by the photoreactive batrachotoxin derivative was identified by antibody mapping of proteolytic fragments. Even after extensive trypsinization, an anti-peptide antibody recognizing an amino acid sequence adjacent to Na channel transmembrane segment IS6 was able to immunoprecipitate up to 70% of the labeled peptides. Analysis of a more complete digestion with trypsin or V8 protease indicated that the batrachotoxin receptor site is formed in part by a portion of domain I. The identification of a specifically immunoprecipitated photolabeled 7.3-kDa peptide containing transmembrane segment S6 from domain I restricted the site of labeling to residues Asn-388 to Glu-429 if V8 protease digestion was complete or Leu-380 to Glu-429 if digestion was incomplete. These results implicate the S6 transmembrane region of domain I of the Na channel alpha subunit as an important component of the batrachotoxin receptor site.


INTRODUCTION

Batrachotoxin (BTX) (^1)is a steroidal alkaloid toxin from skin secretions of South American frogs, Phyllobates aurotaenia and Phyllobates terribilus, which are used by the native Indians of Colombia to make poison blowdarts and arrows(1) . It is one of the most toxic nonproteinaceous substances known and is capable of inducing membrane depolarization at concentrations in the low nanomolar range. The voltage-gated Na channels of excitable membranes are the molecular targets of BTX, and all aspects of Na channel function are altered upon exposure to BTX: inactivation is blocked, single channel conductance is decreased, voltage dependence of activation is shifted to more negative potentials, and selectivity for Na is impaired (reviewed in (2) and (3) ).

Competitive binding studies with radiolabeled neurotoxin analogues have distinguished five distinct receptor sites for neurotoxins on the Na channel, including neurotoxin receptor site 2 which is occupied by the full agonist BTX and the partial agonists veratridine, aconitine, and grayanotoxin which modulate Na channel gating(2, 3) . The binding of BTX at neurotoxin receptor site 2 results in stabilization of an open conformation of the channel. At least four of the five receptor sites have been shown to be located on the 260-kDa alpha subunit, which is composed of four homologous domains (I-IV) containing six putative transmembrane segments (S1-S6; Refs. 4, 5). Site-directed mutagenesis experiments have identified amino acid residues of the alpha subunit that are required for high affinity binding of tetrodotoxin and saxitoxin at neurotoxin receptor site 1(6, 7, 8) . Peptide segments from neurotoxin receptor site 3, which binds alpha-scorpion toxins and sea anemone toxins, and neurotoxin receptor site 5, which binds brevetoxins, have been identified by photoaffinity labeling and peptide mapping with sequence-specific antibodies(9, 10, 11) , and individual amino acid residues that are required for high affinity binding of alpha-scorpion toxins and sea anemone toxins to receptor site 3 have been identified by site-directed mutagenesis(12) .

BTX binding to neurotoxin receptor site 2 is allosterically modulated by other Na channel neurotoxins. The alpha-polypeptide toxins from scorpion and sea anemone(13) , the alpha-cyano-pyrethroid insecticides(3, 14, 15) , and brevetoxin (14, 15) all enhance BTX binding. Other compounds such as tetrodotoxin and saxitoxin(16) , local anesthetics(17, 18) , and the anticonvulsants diphenylhydantoin and carbamazepine (19) decrease BTX-binding affinity. These results indicate that the BTX-binding site is particularly sensitive to conformational alterations induced at distinct sites.

Neurotoxin receptor site 2 is present on Na channels expressed from alpha subunit cDNA alone(20, 21) . Mapping of the peptide segments of the alpha subunit that form receptor site 2 by photoaffinity labeling has not been feasible because the ligands binding at that site have relatively low affinity and are hydrophobic, resulting in low specific binding values. These difficulties can be circumvented by taking advantage of the allosteric enhancement of BTX binding by pyrethroids and the brevetoxin analogue, PbTx-1. This combination of effectors can enhance BTX binding in a purified and reconstituted Na channel preparation up to 1000-fold, reducing the K to a value below 1 nM(15) . In this study, this combination of toxins is used to enhance high affinity binding and covalent incorporation of a photoreactive, radiolabeled BTX derivative, [^3H]BTX-OAB, into purified Na channels, and the major site of incorporation is identified by peptide mapping with anti-peptide antibodies.


EXPERIMENTAL PROCEDURES

Materials

Ecolume was from ICN Biomedicals, Inc. and Soluene was from DuPont NEN. Phosphatidylcholine and phosphatidylethanolamine used for sodium channel reconstitution were from Avanti Polar Lipids and L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin (TPCK-trypsin, from bovine pancreas) was from Worthington. Protease type XVII-B (from Staphylococcus aureus strain V8) and trypsin inhibitor (from soybean) were from Sigma. Prestained molecular weight markers and precast mini-gels were from Novex. [^3H]BTX-B was obtained from DuPont NEN at a specific activity of 51.5 Ci/mmol. RU39568 and RU51049 are synthetic pyrethroid derivatives supplied by Roussel Uclaf (Romainville, France). PbTx-1 was generously supplied by Chiral Corp. (Miami, FL).

Synthesis of [^3H]BTX-OAB

[^3H]BTX-OAB was synthesized as described previously (22) from [^3H]anthranilic acid (47 Ci/mmol) by selective esterification of BTX-A.

[^3H]BTX-B Binding to Reconstituted Na Channels

Binding reactions were initiated by a 4-fold dilution of 50 µl of purified and reconstituted Na channel (5-10 pmol) in standard binding medium(23) . Reconstituted channels were incubated at 25 °C for 16 h with [^3H]BTX-B and other effectors as shown in the figure legends. Binding reactions were stopped by addition of choline wash medium, and samples were filtered through GF/F filters as described previously(24) . Nonspecific binding was determined in the presence of 300 µM veratridine.

Sequence-directed Antibodies

Polyclonal antisera were raised in rabbits against synthetic Na channel peptides (SP) corresponding to sequences of the rat brain type IIA alpha subunit (4, 5) as described previously(25, 26, 27) .

Preparation of Antibodies Bound to Protein A-Sepharose

Protein A-Sepharose was swollen for 20 min at 25 °C in 0.1 M sodium phosphate, pH 8.1, to give a final concentration of 100 mg/ml. One ml of serum was added per 0.75 ml of swollen protein A-Sepharose and mixed by rotation at 25 °C for 30 min or at 4 °C overnight. Supernatants were removed, and the pellets were washed five times with 10 volumes of buffer S (10 mM Tris, adjusted to pH 7.4 with HCl, 150 mM NaCl). The pellet was resuspended in 1 volume of buffer S and used for immunoprecipitation of photolabeled Na channel peptides.

Photolabeling of Reconstituted Sodium Channels

Rat brain Na channels were purified by ion exchange and hydroxylapatite chromatography and affinity chromatography on wheat germ agglutinin-Sepharose as described previously(28) . Solubilized Na channel in detergent solution was quantified by [^3H]saxitoxin binding using a rapid filtration technique (29) . Purified samples containing 250-350 pmol/ml Na channel in Na(2)SO(4) medium were reconstituted into phosphatidylcholine/phosphatidylethanolamine vesicles (65:35, v/v) as described by Feller et al.(30) . Purified and reconstituted Na channels were diluted with 1 volume of standard binding medium (130 mM choline chloride, 50 mM Hepes, adjusted to pH 7.4 with Tris, 5.5 mM glucose, 0.8 mM MgSO(4), 5.4 mM KCl; (31) ) and incubated with 100 nM PbTx-1, 20 µM RU51049, and [^3H]BTX-OAB to give a final concentration of 100-125 nM for 4 h in the dark at 25 °C. An aliquot of this mixture was incubated in the presence of 300 µM veratridine for the determination of nonspecific binding and nonspecific photolabeling. Dithiothreitol was added to a final concentration of 0.25 mM (to reduce nonspecific photolabeling) immediately before ultraviolet irradiation at 4 °C for 30 min using a germicidal lamp ((max) = 254 nm; UVP, Inc.) that was placed 5 cm from the sample. Toxin bound to sodium channels was then separated from free toxin by rapid gel filtration on 2-ml Sephadex G-50 spin columns. This photolabeled sample contained specifically incorporated [^3H]BTX-OAB at 300-600 cpm/µl, corresponding to labeling of approximately 2% of the total alpha subunits.

Proteolytic Cleavage and Immunoprecipitation of [^3H]BTX-OAB-Labeled alpha Subunits

Photolabeled Na channels purified by Sephadex chromatography were solubilized with 0.1% Triton X-100 and treated with TPCK-trypsin at the concentrations shown in the figure legends. Samples were digested for 1 h at 37 °C and then treated with 50 µg/ml trypsin inhibitor, 1% Triton X-100, 150 mM NaCl, and 1 mg/ml globulin-free bovine serum albumin for 10 min at 4 °C. Digested and photolabeled Na channel (approximately 10,000 cpm of [^3H]BTX-OAB per sample) was incubated with mixing by rotation with 100 µl of antibody bound to protein A-Sepharose overnight at 4 °C. Supernatants were removed, and the pellets were washed three times with 5 volumes of buffer S. The proteins were solubilized from the pellet by incubation with 8% SDS and analyzed by scintillation spectroscopy.

SDS-PAGE and Gel Slicing

Photolabeled samples were prepared for SDS-PAGE analysis by solubilization with 0.1% Triton X-100 and digestion with 100 µg/ml TPCK-trypsin overnight at 37 °C. Digested samples were incubated with 50 µg/ml trypsin inhibitor for 10 min at 4 °C and then reduced for 10 min at 25 °C with 10 mM dithiothreitol in the presence of 0.1% (w/v) SDS in 50 mM ammonium bicarbonate buffer adjusted to pH 7.8. Iodoacetamide (70 mM final concentration) was used to carboxymethylate the samples by incubation at 25 °C for 1 h. Further digestion of samples was carried out by incubation with 100 µg/ml V8 protease overnight at 37 °C. Digestion was terminated by addition of 200 µg/ml aprotinin and 10 µg/ml leupeptin for 10 min at 4 °C. Samples were immunoprecipitated by incubation with 1% Triton X-100, 150 mM NaCl, and protein A-Sepharose-bound antibody overnight with rotation at 4 °C. Supernatants were removed, and the pellets were washed two times with 5 volumes of buffer S. For analysis of [^3H]BTX-OAB bound to immunoprecipitated Na channel peptides, a variety of gel systems were used as described below. Prestained molecular mass standards were used to determine the molecular mass of the Na channel peptides. To determine protein-bound radioactivity, individual gel lanes were manually cut into 1-3-mm slices, and radioactivity was eluted in 5% (v/v) Soluene in Ecolume according to the manufacturer's instructions.

Electrophoresis Methods

The 7% porous gel system of Doucet et al. (32) was used to analyze radiolabeling of the intact Na channel alpha subunit. Three gel systems were used to analyze small peptides in this study. System 1 was a Tricine-based gel system described by Schägger and van Jagow ((33) ; stacking gel, 4% T, 3% C; spacer gel, 10 T%, 3% C; separating gel, 16.5% T, 6% C, where T is total monomer and C is cross-linker) poured as a large gel. System 2 was a commercially prepared 16.5% Tricine mini-gel system from Novex. System 3 was a 10-20% gradient Tricine mini-gel system from Novex.


RESULTS

Characterization of [^3H]BTX-OAB Binding to Purified and Reconstituted Sodium Channels

Previous work (15) has demonstrated specific, high affinity binding of [^3H]BTX to neurotoxin site 2 on sodium channels purified from rat brain and reconstituted in phospholipid vesicles. In order to demonstrate that the radiolabeled, photoreactive derivative of BTX, [^3H]BTX-OAB (Fig. 1), has the same binding characteristics as [^3H]BTX-B, we examined the binding of [^3H]BTX-B and [^3H]BTX-OAB to the same reconstituted Na channel preparation. Specific binding of both [^3H]BTX-B and [^3H]BTX-OAB is inhibited by saturation of receptor site 2 by unlabeled veratridine with half-maximal inhibition at approximately 8 µM (Fig. 2, solid symbols), in good agreement with the value of 7 µM observed for synaptosomes(13) . Using a concentration of 300 µM unlabeled veratridine to measure nonspecific binding, specific binding was determined to be 92-94% of total binding using either radiolabeled BTX derivative. No saturable component of [^3H]BTX-B binding was observed in parallel experiments with sodium channels that had been heat-inactivated by incubation at 60 °C for 2 min (Fig. 2, open circles) or with phospholipid vesicles without added protein (Fig. 2, open squares). The loss of binding at an elevated temperature provides evidence that conformational integrity of the purified Na channel is a requirement for high affinity interaction with BTX, as previously observed for brevetoxins(11) , saxitoxin, and alpha-scorpion toxin(24) .


Figure 1: Structure of BTX and its derivatives. The positions of ^3H labels are shown by asterisks. Batrachotoxinin-A (BTX-A) is the nontoxic natural precursor of batrachotoxin from which both radiolabeled derivatives (bottom two structures) were synthesized.




Figure 2: Competitive displacement of [^3H]BTX-B bound to reconstituted Na channels by unlabeled veratridine. Binding of [^3H]BTX-B (17 nM, solid circles) and [^3H]BTX-OAB (10 nM, solid squares) to reconstituted Na channels was measured as described under ``Experimental Procedures'' in the presence of the indicated concentrations of veratridine. Control binding of [^3H]BTX-B to heat-inactivated and reconstituted Na channels (open circles) and reconstituted phospholipids (open squares) was also determined.



Synergistic Effects of Pyrethroids and Brevetoxins on BTX Binding

[^3H]BTX-B binding to purified and reconstituted rat brain Na channel is enhanced by pyrethroids(15) . In that study, specific [^3H]BTX-B binding was 99% of total binding in the presence of 10 µM RU39568, the highest level of specific BTX binding yet demonstrated. In the present study, half-maximal enhancement of [^3H]BTX-B binding by RU39568 was observed at approximately 2 µM (Fig. 3A, solid circles), consistent with previous studies(15) , and the half-maximal effect of RU51049 was achieved at about 600 nM (Fig. 3A, solid squares). The maximal enhancement of BTX binding in the presence of 100 µM RU51049 is approximately 30% greater than that observed with RU39568. Binding of the pyrethroids, RU51049 and RU39568, and the brevetoxin, PbTx-1, to their receptor sites in purified Na channel preparations reconstituted into phospholipid vesicles leads to a marked increase in specific binding of BTX at receptor site 2 (Fig. 3B). PbTx-1 increases the level of specific binding observed in the presence of a saturating concentration of either pyrethroid. No specific binding of [^3H]BTX-B was observed with purified and solubilized Na channel preparations that had not been reconstituted into vesicles, which is consistent with previous studies(29) .


Figure 3: Enhancement of specific [^3H]BTX-B binding by RU39568, RU51049, and PbTx-1. A, [^3H]BTX-B binding to reconstituted Na channels was measured as described under ``Experimental Procedures'' in the presence of 5 nM [^3H]BTX-B and increasing concentrations of RU39568 (solid circles) or RU51049 (solid squares). B, [^3H]BTX-B binding was measured in the presence of 0.5 nM [^3H]BTX-B and 10 µM RU pyrethroid with and without 100 nM PbTx-1 in the presence (stippled bars) or absence (solid bars) of 300 µM veratridine for determination of nonspecific and total binding, respectively. Binding of [^3H]BTX-B to purified soluble Na channel was measured in the presence of 10 µM RU51049 and 100 nM PbTx-1. Samples were incubated at 25 °C for 17 h for determination of maximum allosteric interaction.



Specific Photolabeling of Reconstituted Sodium Channels by [^3H]BTX-OAB in the Presence of RU51049 and PbTx-1

Purified and reconstituted Na channels were specifically photolabeled by [^3H]BTX-OAB in the presence of 20 µM RU51049 and 100 nM PbTx-1. Analysis of specifically labeled, reconstituted Na channels by SDS-PAGE, gel slicing, and scintillation counting revealed a single peak of covalently incorporated [^3H]BTX-OAB with an apparent molecular mass of 240 kDa, consistent with covalent labeling of the alpha subunit (Fig. 4, solid circles). Samples labeled in the presence of an excess of unlabeled veratridine did not contain any [^3H]BTX-OAB covalently attached to proteins (Fig. 4, open circles). Some degradation of the specifically labeled protein was observed as a band of radioactivity at approximately 50 kDa, which is expected since a 4-h incubation at 25 °C was used in this experiment. Consistent with this result, previous studies have indicated that the Na channel alpha subunit contains a relatively protease-resistant domain of 50-70 kDa (9) .


Figure 4: Specific photolabeling of purified Na channels. Reconstituted Na channels were purified and photolabeled with 90 nM [^3H]BTX-OAB as described under ``Experimental Procedures'' in the absence (solid circles) or presence (open circles) of 300 µM veratridine. Samples were analyzed by SDS-PAGE (7% porous reducing gel system; Doucet et al.(32) ), and the incorporation of photolabel was determined in 3-mm gel slices by extraction and scintillation counting as described under ``Experimental Procedures.'' The migration of molecular mass standards (kDa) are indicated by arrows.



Isolation and Characterization of Smaller Proteolytic Fragments Labeled with [^3H]BTX-OAB

To localize the position of the covalently attached photolabel, the reconstituted Na channel labeled with [^3H]BTX-OAB was digested at lysine and arginine residues with TPCK-trypsin. The digested, photolabeled fragments were then probed by immunoprecipitation with a series of sequence-directed antibodies recognizing regions of the alpha subunit within or bordering each of the four homologous domains as illustrated in Fig. 5A. All of the antibodies specifically immunoprecipitated the intact alpha subunit. The amount of radioactivity bound by all of the Na channel antibodies progressively decreased with increasing trypsin concentrations, suggesting that the antibody binding sites were separated from the [^3H]BTX-OAB incorporation site upon proteolysis (Fig. 5B). After cleavage of the [^3H]BTX-OAB-labeled alpha subunit with increasing concentrations of trypsin, anti-SP1, directed against a sequence immediately following transmembrane segment IS6, immunoprecipitated over 70% of the total specifically photolabeled channel at the highest concentration of trypsin tested (Fig. 5B). The antibodies within or bordering domains II, III, and IV recognized only a small fraction of the radioactivity (less than 20%) after extensive trypsinization. These results indicate that a substantial fraction of covalently incorporated [^3H]BTX-OAB is located within domain I.


Figure 5: Immunoprecipitation of peptides covalently labeled by [^3H]BTX-OAB. A, recognition sites of anti-peptide antibodies. Antibodies directed against synthetic peptides corresponding to different sequences of the alpha subunit of the type IIA sodium channel were prepared as described (Gordon et al.(25, 26) ). Antibodies were directed against synthetic sodium channel peptides corresponding to the amino acid sequences 355-372 (SP31), 382-400 (SP28), 427-445 (SP1), 468-504 (SP11), 531-547 (SP32), 708-722 (SP15), 1145-1164 (SP20), 1480-1498 (SP14), 1541-1561 (SP19), 1736-1753 (SP29), 1789-1798 (SP13). B, immunoprecipitation of [^3H]BTX-OAB-labeled Na channel peptide fragments from proteolytic cleavage by trypsin. Photolabeled reconstituted Na channels were digested with increasing concentrations of TPCK-trypsin, and the resulting peptide fragments were probed with the indicated antibodies as described under ``Experimental Procedures.'' TPCK-trypsin concentrations for each antibody treatment were as follows (from left to right): 0.3, 1, 10, 100 µg/ml. Values are expressed as the percentage of total cpm immunoprecipitated without trypsin treatment.



The site of BTX covalent labeling of the Na channel alpha subunit was more precisely localized by more extensive proteolytic cleavage at lysine and arginine residues with trypsin and at glutamic acid and aspartic acid residues with V8 protease from S. aureus. Under the conditions for proteolysis described in Fig. 6A, approximately 50% of the total radioactivity was precipitable by anti-SP11 antibody and 70% by anti-SP1 antibody after cleavage with 10 µg/ml trypsin for 1 h. These antibodies, directed against peptides within the first 60 amino acids at the intracellular side of transmembrane segment IS6, completely lose their ability to recognize alpha subunit-bound [^3H]BTX-OAB upon digestion with 100 µg/ml V8 protease for 1 h (Fig. 6B). However, anti-SP31 and anti-SP28, antibodies directed against peptides within the first 50 amino acids extracellular to transmembrane segment IVS6, were able to precipitate 30-60% of radioactivity after cleavage with trypsin (Fig. 6A) and over 50% of the total specific radioactivity after cleavage with V8 protease (Fig. 6B). Anti-SP15, anti-SP14, and anti-SP19, which are directed against sequences farther toward the carboxyl terminus, do not immunoprecipitate a significant amount of photolabel (Fig. 6, A and B). These results indicate that the site of [^3H]BTX-OAB covalent labeling is located to the amino-terminal side of the anti-SP1 recognition peptide.


Figure 6: Immunoprecipitation of peptides labeled by [^3H]BTX-OAB after proteolytic cleavage by TPCK-trypsin and V8 protease. Photolabeled and reconstituted Na channel was digested in the presence of 10 µg/ml TPCK-trypsin (A) or 100 µg/ml V8 protease (B) for 2 h at 37 °C, and the resulting peptide fragments were probed with the indicated antibodies as described under ``Experimental Procedures.'' Values are expressed as the percentage of total cpm immunoprecipitated by each antibody with no prior protease treatment.



Photolabeling of a 7-kDa Peptide by [^3H]BTX-OAB

A complete tryptic digest was obtained by covalently labeling the purified and reconstituted Na channel with [^3H]BTX-OAB and subjecting the labeled protein to digestion with 100 µg/ml trypsin overnight at 37 °C and then with V8 protease under the same conditions overnight. This extensively digested preparation was used to restrict further the sites of labeling by [^3H]BTX-OAB to small Na channel peptides recognized by anti-SP28. Based on the results of Fig. 6, we would expect the smallest labeled peptides from such complete digestions to be recognized by anti-SP28, but not anti-SP1. Labeled peptide fragments were incubated with either anti-SP1, anti-SP28, or preimmune rabbit IgG and analyzed by SDS-PAGE in highly cross-linked gels. Anti-SP1 and anti-SP28 both recognized photolabeled fragments with apparent molecular masses of 60 and 32 kDa (Fig. 7A, solid symbols); however, IgG from preimmune serum did not precipitate significant amounts of the photolabeled channel peptides (Fig. 7A, open circles). Only anti-SP28 precipitated a photolabeled peptide with a molecular mass of approximately 6 kDa (Fig. 7A, solid triangles). Some reversibly bound photolabel, which was not removed by washing prior to electrophoresis, was observed at the gel dye front. Immunoprecipitation of the 6-kDa peptide by anti-SP28 was specific, because neither preimmune IgG nor anti-SP28 recognize this small labeled peptide.


Figure 7: SDS-PAGE analysis of tryptic peptides from [^3H]BTX-OAB-labeled Na channel. A, samples were labeled with [^3H]BTX-OAB, digested with 100 µg/ml TPCK-trypsin at 37 °C overnight, then with 100 µg/ml V8 protease at 37 °C overnight, and analyzed on a Tricine SDS-PAGE gel (system 2) as described under ``Experimental Procedures.'' The labeled peptides precipitated by anti-SP28 (solid triangles), anti-SP1 (solid circles), or preimmune rabbit IgG (open circles) are shown. The migration positions of molecular mass standards are indicated by the arrows. The gel dye front is indicated by df. B, estimations of molecular size of the [^3H]BTX-OAB-labeled peptide are shown. The three different gel systems used are described under ``Experimental Procedures.'' The average molecular size determined in these four experiments is 7.3 kDa.



Experiments like the one illustrated in Fig. 7were carried out with several preparations of purified and reconstituted Na channels, two different preparations of [^3H]BTX-OAB, and three different SDS-PAGE separation systems with similar results. Although the small 6-7-kDa peptide, which can be precipitated by anti-SP28, migrates close to the dye front in all of the SDS-PAGE systems used, the estimation of size is consistent in all three gel systems (Fig. 7B). These results indicate that [^3H]BTX-OAB is covalently incorporated into a peptide of about 7.3 kDa containing the anti-SP28 antibody recognition site.

Examination of the amino acid sequence of the alpha subunit near the SP28 peptide (Fig. 8) allows identification of the photolabeled fragment obtained from extensive cleavage with trypsin and V8 protease. In domain I, the peptide which includes all of the anti-SP28 recognition sequence from the trypsin cleavage site, Leu-380, to the V8 protease cleavage site, Glu-429, has a calculated molecular mass of 7.3 kDa (Fig. 8). Trypsin cleavage within peptide SP28 was previously found to occur only under extreme conditions(9) , so cleavage at Arg-395 or Lys-399 is unlikely. More complete cleavage by V8 protease at Glu-387 within the SP28 sequence might yield the peptide from Asn-388 to Glu-429 with a calculated molecular mass of 6.0 kDa, which contains all but 6 residues of the sequence of peptide SP28. Because peptides are linked through their amino termini to bovine serum albumin for immunization, the first few amino acid residues of the peptide sequence may not be essential for antibody recognition of the peptide. Thus, the possible [^3H]BTX-OAB-binding peptides containing the SP28 sequence begin 13 or 21 amino acid residues on the extracellular side of transmembrane segment IVS6, contain the entire transmembrane segment IVS6, and 3 amino acids on the intracellular side of segment IVS6.


Figure 8: Amino acid sequence of the batrachotoxin-binding region on the Na channel alpha subunit. The primary structure and antibody recognition sequences of the photolabeled peptides from domain I are shown. Antibody recognition sequences (underlined), transmembrane segments (boxed), and expected sites of trypsin (arrows) and V8 protease (asterisks) cleavage are indicated.



Less extensive cleavage with trypsin alone yields peptides that contain the recognition sites for anti-SP1 and anti-SP11 on the intracellular, carboxyl-terminal side of transmembrane segment IS6 (Fig. 6A). These peptides must contain sequences extending beyond Ser-504 (Fig. 8). In contrast, cleavage with V8 protease removes the recognition site for these two antibodies (Fig. 6B) by cleavage at one of the numerous Glu residues in the SP1 sequence (Fig. 8). Cleavage of the SP1 peptide from transmembrane segment IS6 by treatment with V8 protease and resistance of the SP28 peptide within the alpha subunit to cleavage by trypsin as observed here are consistent with previous work on peptide mapping of the alpha-scorpion toxin receptor site(9, 34) .


DISCUSSION

High Affinity Binding of a Photoreactive BTX Derivative to Neurotoxin Receptor Site 2 on Purified and Reconstituted Sodium Channels

The synthesis of a photoreactive, radiolabeled derivative of BTX, [^3H]BTX-OAB, has made possible the biochemical localization of a component of the BTX receptor site. In the presence of alpha-scorpion toxin, this ligand binds to the BTX site of Na channels in rat brain synaptoneurosomes with a K(D) of 23 nM(22) . In the present study, the Na channel activators, RU51049 and PbTx-1, are used to allosterically enhance [^3H]BTX-OAB binding, resulting in a K(D) of less than 1 nM and a specific binding value of greater than 90%.

We have found that in the presence of the pyrethroid, RU51049, and the brevetoxin, PbTx-1, both [^3H]BTX-B and [^3H]BTX-OAB bound to purified and reconstituted sodium channels with similar high affinity. No high affinity binding of [^3H]BTX-B was present in heat-inactivated sodium channel preparations or to phospholipid alone. These results establish that high affinity binding of BTX derivatives requires the native conformation of the purified sodium channel and that neurotoxin receptor site 2 is present in active form on the solubilized, purified, and reconstituted sodium channel. Covalent labeling of purified and reconstituted Na channel with [^3H]BTX-OAB provided the initial material used for biochemical localization of a peptide sequence that contributes to formation of neurotoxin receptor site 2.

Location of the BTX Receptor Site Near Transmembrane Segment IS6 in Domain I

The photoreactive derivative of BTX, [^3H]BTX-OAB, is incorporated specifically into the rat brain Na channel by photoactivation of the ligand after equilibrium binding is complete. The specific reaction of this derivative with a 240-kDa protein implicates the alpha subunit in BTX binding. Mapping of the peptide segment that is covalently labeled by [^3H]BTX-OAB using sequence-directed antibodies identifies one transmembrane segment as a component of the BTX receptor site. After proteolytic cleavage, the amount of radioactivity bound by each sequence-directed antibody progressively decreased as antibody-binding sequences were separated from the [^3H]BTX-OAB incorporation site by proteolysis. However, even after extensive trypsinization, the anti-peptide antibody recognizing an amino acid sequence adjacent to transmembrane segment IS6 was able to immunoprecipitate up to 70% of the labeled peptides. In contrast, antibodies recognizing sequences within or adjacent to domains II, III, and IV do not immunoprecipitate labeled peptides. These results implicate a segment in domain I in formation of the BTX receptor site.

Further localization of the site of covalent labeling by [^3H]BTX-OAB was achieved by analysis of immunoprecipitated fragments with antibodies recognizing peptide sequences within or near domain I after more extensive proteolytic cleavage with TPCK-trypsin and V8 protease. After trypsinization, two anti-peptide antibodies recognizing the amino acid sequence on the intracellular side of transmembrane segment IS6 were able to immunoprecipitate at least 50% of the [^3H]BTX-OAB-labeled peptides, and two anti-peptide antibodies recognizing the amino acid sequence on the extracellular side of this same transmembrane region were able to immunoprecipitate 30-60% of the labeled peptides. In contrast, after treatment with V8 protease, the ability of the two antibodies recognizing the intracellular amino acid sequences to precipitate the labeled peptide was completely lost, whereas the antibodies recognizing the sequences extracellular to IS6 retained their ability to precipitate the labeled peptide. These results indicate that the BTX receptor site is formed by a portion of domain I and that the site of photolabeling does not include the amino acids to the carboxyl-terminal side of transmembrane region IS6.

A more precise biochemical localization of the site of covalent labeling by [^3H]BTX-OAB was achieved by SDS-PAGE analysis of cleavage products from proteolytic digestions of labeled Na channels with both TPCK-trypsin and V8 protease. The identification of a specifically immunoprecipitated 7-kDa peptide from domain I restricts the labeled peptide fragment to residues Asn-388 to Glu-429 (calculated molecular mass, 6.0 kDa, Fig. 8) or to the region from Leu-380 to Glu-429 (7.3 kDa) if V8 protease cleavage is incomplete. When estimations of molecular mass from three different gel systems are averaged together, the value for the radiolabeled, immunoprecipitated peptide is 7.3 kDa, in excellent agreement with the size of the predicted cleavage product from Leu-380 to Glu-429.

The photoreactive azide of [^3H]BTX-OAB is positioned on an aromatic side chain known to be important in conferring toxicity to BTX because the precursor BTX-A, which lacks this aromatic moiety, is nontoxic(3) . Therefore, the photoreactive side chain most likely interacts with an integral part of the receptor site for BTX on the Na channel alpha subunit. Thus, our results implicate transmembrane segment IS6 in direct interaction with bound BTX in receptor site 2.

Analysis of Covalent Labeling by Antibody Mapping of Labeled Peptides

Photoaffinity labeling of ion channels and other minor membrane proteins is an effective method for identification of their functional components. However, the low level of incorporation of most photolabels and the low abundance and hydrophobicity of the labeled proteins often prevent high resolution analysis of the labeled products by complete purification of the labeled peptides and amino acid sequence determination. Identification of labeled peptides by mapping with sequence-directed anti-peptide antibodies has proven to be a powerful and reliable method of peptide identification. This approach has been used to identify covalently labeled receptor sites for dihydropyridines (35, 36) and phenylalkylamines (37) on L-type Ca channels and for alpha-scorpion toxin(34) , brevetoxins (11) , and BTX (this paper) on Na channels. Subsequent analysis by site-directed mutagenesis has identified individual amino acid residues within or near the site of photoaffinity labeling that are required for binding of dihydropyridines (38) and phenylalkylamines (39) to L-type Ca channels and alpha-scorpion toxin to Na channels(12) . The photoactive derivatives of small organic ligands have closely mapped the receptor site residues (35, 36, 37, 38, 39) ; however, the site of alpha-scorpion toxin binding has only been approximated by photolabeling due to the relatively large size of the ligand(12) . Mutagenesis studies have confirmed the accuracy of the photoaffinity labeling and antibody mapping approaches and provided a higher resolution view of the components of these receptor sites. Analysis of the region of transmembrane segment IS6 by site-directed mutagenesis should yield additional insight into the molecular requirements for high affinity binding of BTX.

Allosteric Interactions with the BTX Receptor Site

A model for allosteric interactions with the BTX receptor site can be proposed by taking into consideration the lipophilic nature of the toxin, its physiological effects, and the location of the photolabeled peptide. BTX can gain access to its binding site from either side of the membrane, since BTX-induced membrane depolarization is observed in squid giant axon when the toxin is applied either internally or externally to the perfusion medium(40) . The BTX molecule is approximately 12 Å long, much smaller than the width of the phospholipid bilayer. Therefore, the BTX-binding site may be located within a transmembrane region of the alpha subunit, in a relatively inaccessible position in the resting Na channel conformation. Activation of the Na channel by repetitive depolarization dramatically accelerates BTX binding(41) . In addition, several chemical activators, including the pyrethroids, RU39568 and RU51049, and the brevetoxin, PbTx-1, induce a conformational change which results in the greater accessibility and higher affinity of BTX to its receptor site. The site of brevetoxin binding has been localized to a transmembrane region at the interface of domains I and IV that includes transmembrane segment IS6(11) , to which BTX also binds. Thus, it is possible that multiple sites for hydrophobic toxin binding include determinants within this transmembrane segment and allow discrete changes in three-dimensional structure of the Na channel caused by binding of one toxin to affect the binding of others through allosteric interactions.

BTX binding is also affected by binding of toxins to more distant regions of the Na channel. Site-directed mutagenesis studies have identified the amino acid residues lining the mouth of the channel pore between transmembrane segments 5 and 6 in each of the four domains as critical for binding of tetrodotoxin and saxitoxin at neurotoxin receptor site 1(6, 7, 8) . The binding of these toxins to site 1 has been shown to allosterically decrease the binding of BTX to site 2 under some conditions(16) .

The interactive nature of BTX binding provides evidence that neurotoxin receptor site 2 is located in a region of the Na channel that exhibits considerable structural flexibility. Not only does the binding of other toxins affect the affinity of BTX binding through allosteric alteration of site 2, but binding of BTX itself results in a conformational change of the channel. Upon BTX binding to the Na channel, the flux of relatively impermeant cations increases, indicating that the size of the ion selectivity filter is increased, inactivation is blocked, and the voltage dependence of activation is shifted to more negative potentials (see review by Brown et al.(42) ). These alterations in channel function indicate that the Na channel has multiple neurotoxin binding sites that are located in areas of great conformational flexibility. Upon binding of neurotoxins to the Na channel, conformational changes occur that alter the position of toxin binding sites with respect to one another and change channel gating kinetics. By locating the precise positions of toxin receptor sites and by understanding the relationship of these sites to one another, the alterations of normal gating processes following toxin binding and mechanisms of allosteric interaction among bound toxins will be clarified.


FOOTNOTES

*
This work was supported by Research Grant NS15751 (to W. A. C.) from the National Institutes of Health, a National Research Service Award F32 ES 05586 (to V. L. T.), and Research Grant DA07237 (to G. B. B.) from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

(^1)
The abbreviations used are: BTX, batrachotoxin; [^3H]BTX-B, tritiated batrachotoxinin-A 20-alpha-benzoate, [benzoyl-2,5-]; [^3H]BTX-OAB, tritiated batrachotoxinin-A orthoazidobenzoate, [benzoyl-2,5-]; PbTx, brevetoxin from Ptychodiscus brevis; TPCK-trypsin, L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin; SP, sodium channel peptide; PAGE, polyacrylamide gel electrophoresis; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; V8 protease, protease type XVII-B (from Staphylococcus aureus strain V8).


ACKNOWLEDGEMENTS

We thank Dr. John Daly for his generous gift of batrachotoxinin-A used in this study and Chiral Corp. for the gift of PbTx-1. We are grateful to Roussel Uclaf for supplying us with the pyrethroids RU39568 and RU51049. We acknowledge Carl Baker for expert technical assistance with purification of sodium channels.


REFERENCES

  1. Myers, C. W., Daly, J. W., and Malkin, B. (1978) Bull. Am. Mus. Nat. Hist. 161, 307-360
  2. Catterall, W. A. (1980) Annu. Rev. Pharmacol. Toxicol. 20, 15-43 [CrossRef][Medline] [Order article via Infotrieve]
  3. Brown, G. B. (1988) Int. Rev. Neurobiol. 29, 76-116
  4. Noda, M., Ikeda, T., Kayano, T., Suzuki, H., Takeshima, H., Kurasaki, M., Takahashi, H., and Numa, S. (1986) Nature 320, 188-192 [Medline] [Order article via Infotrieve]
  5. Auld, V. J., Goldin, A. L., Krafte, D. S., Marshall, J., Dunn, J. M., Catterall, W. A., Lester, H. A., Davidson, N., and Dunn, R. J. (1988) Neuron 1, 449-461 [CrossRef][Medline] [Order article via Infotrieve]
  6. Noda, M., Suzuki, H., Numa, S., and Stühmer, W. (1989) FEBS Lett. 259, 213-216 [CrossRef][Medline] [Order article via Infotrieve]
  7. Terlau, H., Heinemann, S. H., Stühmer, W., Pusch, M., Conti, F., Imoto, K., and Numa, S. (1991) FEBS Lett. 293, 93-96 [CrossRef][Medline] [Order article via Infotrieve]
  8. Satin, J., Kyle, J. W., Chen, M., Bell, P., Cribbs, L. L., Fozzard, H. A., and Rogart, R. B. (1992) Science 256, 1202-1205 [Medline] [Order article via Infotrieve]
  9. Tejedor, F. J, and Catterall, W. A. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8742-8746 [Abstract]
  10. Thomsen, W. J., and Catterall, W. A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 10161-10165 [Abstract]
  11. Trainer, V. L., Baden, D. G., and Catterall, W. A. (1994) J. Biol. Chem. 269, 19904-19909 [Abstract/Free Full Text]
  12. Rogers, J. (1996) Biophys. J. 70, A319
  13. Catterall, W. A., Morrow, C. S., Daly, J. W., and Brown, G. B. (1981) J. Biol. Chem. 256, 8922-8927 [Free Full Text]
  14. Lombet, A., Mourre, C., and Lazdunski, M. (1988) Brain Res. 459, 44-53 [Medline] [Order article via Infotrieve]
  15. Trainer, V. L., Moreau, E., Guedin, D., Baden, D. G., and Catterall, W. A. (1993) J. Biol. Chem. 268, 17114-17119 [Abstract/Free Full Text]
  16. Brown, G. B. (1986) J. Neurosci. 6, 2064-2070 [Abstract]
  17. Creveling, C. R., McNeal, E. T., Daly, J. W., and Brown, G. B. (1983) Mol. Pharmacol. 23, 350-358 [Abstract]
  18. Postma, S. W., and Catterall, W. A. (1984) Mol. Pharmacol. 25, 219-225 [Abstract]
  19. Willow, M., and Catterall, W. A. (1982) Mol. Pharmacol. 22, 627-635 [Abstract]
  20. Scheuer, T., Auld, V. J., Boyd, S., Offord, J., Dunn, R., and Catterall, W. A. (1990) Science 247, 854-858 [Medline] [Order article via Infotrieve]
  21. Wang, G. K., and Wang, S. Y. (1994) Pflügers Arch. Eur. J. Physiol. 427, 309-316
  22. Casebolt, T. L., and Brown, G. B. (1993) Toxicon 31, 1113-1122 [Medline] [Order article via Infotrieve]
  23. Sharkey, R. G., Jover, E., Couraud, F., Baden, D. G., and Catterall, W. A. (1986) Mol. Pharmacol. 31, 273-278 [Abstract]
  24. Tamkun, M. M., Talvenheimo, J. A., and Catterall, W. A. (1984) J. Biol. Chem. 259, 1676-1688 [Abstract/Free Full Text]
  25. Gordon, D., Merrick, D., Auld, V., Dunn, R., Goldin, A. L., Davidson, N., and Catterall, W. A. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 8682-8686 [Abstract]
  26. Gordon, D., Merrick, D., Wollner, D. A., and Catterall, W. A. (1988) Biochemistry 27, 7032-7038 [Medline] [Order article via Infotrieve]
  27. Orth, D. N. (1979) in Methods of Hormone Radioimmunoassay (Jaffe, B. M., and Berman, H. R., eds) pp. 245-284, Academic Press, New York
  28. Hartshorne, R. P., and Catterall, W. A. (1984) J. Biol. Chem. 259, 1667-1675 [Abstract/Free Full Text]
  29. Catterall, W. A., Morrow, C. S., and Hartshorne, R. P. (1979) J. Biol. Chem. 254, 11379-11387 [Medline] [Order article via Infotrieve]
  30. Feller, D. J., Talvenheimo, J. A., and Catterall, W. A. (1985) J. Biol. Chem. 260, 11542-11547 [Abstract/Free Full Text]
  31. Sharkey, R. G., Beneski, D. A., and Catterall, W. A. (1984) Biochemistry 23, 6078-6086 [Medline] [Order article via Infotrieve]
  32. Doucet, J. P., Murphy, B. J., and Tuana, B. S. (1990) Anal. Biochem. 190, 209-211 [Medline] [Order article via Infotrieve]
  33. Schägger, H., and van Jagow, G. (1987) Anal. Biochem. 166, 368-379 [Medline] [Order article via Infotrieve]
  34. Tejedor, F. J., and Catterall, W. A. (1990) Cell. Mol. Neurobiol. 10, 257-265 [Medline] [Order article via Infotrieve]
  35. Nakayama, H., Taki, M., Striessnig, J., Glossman, H., Catterall, W. A., and Kanaoka, Y. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9203-9207 [Abstract]
  36. Striessnig, J., Murphy, B. J., and Catterall, W. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10769-10773 [Abstract]
  37. Striessnig, J., Glossman, H., and Catterall, W. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9108-9112 [Abstract]
  38. Peterson, B. Z., Tanada, T., and Catterall, W. A. (1996) J. Biol. Chem. 271, 5293-5296 [Abstract/Free Full Text]
  39. Hockerman, G. H., Johnson, B. P., Scheuer, T., and Catterall, W. A. (1995) J. Biol. Chem. 270, 22119-22122 [Abstract/Free Full Text]
  40. Narahashi, T., Albuquerque, E. X., and Deguchi, T. (1971) J. Gen. Physiol. 58, 54-70 [Abstract/Free Full Text]
  41. Khodorov, B. I., and Revenko, S. V. (1979) Neuroscience 4, 1315-1330 [Medline] [Order article via Infotrieve]
  42. Brown, G. B., Gaupp, J. E., and Olsen, R. W. (1988) Mol. Pharmacol. 34, 54-59 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.